MENTER, A.; BLAUVELT, A.; STROBER, B.; COLOMBO, M.; KISA, R.; KUNDU, S.; BANERJEE, S.; LEONARDI, C. Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s72, 2020. DOI: 10.25251/skin.4.supp.72. Disponível em: https://www.jofskin.org/index.php/skin/article/view/1105. Acesso em: 15 jun. 2024.